BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Integrated DNA Technologies Release: Bringing NGS to the Clinic: What Can We Expect?


2/7/2013 12:20:39 PM

CORALVILLE, IA – 7th February 2013 – Integrated DNA Technologies (IDT), the world leader in oligonucleotide synthesis, speaks with Dr Elaine Mardis, an expert in DNA sequencing, institute Co-director, and Director of Technology Development at The Genome Institute (Washington University, St Louis, MO, USA), in the most recent edition of the IDT newsletter DECODED. The interview discusses the rising use of Next Generation Sequencing (NGS), with particular emphasis on its role in cancer care, and reveals how IDT xGen™ Lockdown™ Probes have offered Dr Mardis an effective solution for exome sequencing and target capture in her lab. She also shares her perspective on possible future developments in NGS and the challenges to be overcome before we see its routine implementation in the clinic.

Within the article Dr Mardis refers to the significant potential of NGS for disease detection and monitoring, and the subsequent impact on patient care. She explains, “NGS gives us this great advantage of generating data that is very comprehensive, yet available to us in a very short timeframe”. This extensive, patient specific data is key, particularly for individuals suffering with cancer, as it allows diagnoses and the subsequent implementation of personalized treatment plans based on the genomic make-up of the malignancy. However, such extensive data production also poses a hurdle, placing extreme demands on computational resources and bioinformatics expertise for data analysis and medical interpretation.

Throughout the interview Dr Mardis raises further interesting avenues for the future progression and implementation of NGS in the clinic. To read more, access the complete article in this quarter’s edition of DECODED.

For additional information on xGen Lockdown Probes and other NGS reagents, please visit www.idtdna.com. Follow us on twitter @idtdna for real-time updates and insights.

About IDT

Integrated DNA Technologies (IDT) is the largest supplier of custom nucleic acids in the world, serving academic, government, and commercial researchers in biotechnology, clinical diagnostics, and pharmaceutical development. IDT's primary business is the manufacture of custom, synthetic DNA and RNA oligonucleotides. Today, IDT synthesizes and ships an average of 36,000 custom oligos per day to more than 86,000 customers worldwide. IDT manufacturing locations include facilities in Coralville, Iowa, USA; San Diego, California, USA; Leuven, Belgium; and Singapore. For more information visit www.idtdna.com.

Integrated DNA Technologies

800-328-2661 (US & Canada)

+1 319-626-8400 (outside US)

productinfo@idtdna.com

www.idtdna.com



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES